These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 29559167)

  • 1. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
    Ermlich SJ; Andrews CP; Folkerth S; Rupp R; Greenberg D; McFetridge RD; Hartzel J; Marchese RD; Stek JE; Abeygunawardana C; Musey LK
    Vaccine; 2018 Oct; 36(45):6875-6882. PubMed ID: 29559167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.
    Stacey HL; Rosen J; Peterson JT; Williams-Diaz A; Gakhar V; Sterling TM; Acosta CJ; Nolan KM; Li J; Pedley A; Benner P; Abeygunawardana C; Kosinski M; Smith WJ; Pujar H; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):530-539. PubMed ID: 30648919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
    Greenberg D; Hoover PA; Vesikari T; Peltier C; Hurley DC; McFetridge RD; Dallas M; Hartzel J; Marchese RD; Coller BG; Stek JE; Abeygunawardana C; Winters MA; MacNair JE; Pujar NS; Musey L
    Vaccine; 2018 Oct; 36(45):6883-6891. PubMed ID: 30244873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
    Rupp R; Hurley D; Grayson S; Li J; Nolan K; McFetridge RD; Hartzel J; Abeygunawardana C; Winters M; Pujar H; Benner P; Musey L
    Hum Vaccin Immunother; 2019; 15(3):549-559. PubMed ID: 30689507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).
    Platt HL; Cardona JF; Haranaka M; Schwartz HI; Narejos Perez S; Dowell A; Chang CJ; Dagan R; Tamms GM; Sterling T; Morgan L; Shi Y; Pedley A; Musey LK; Buchwald UK
    Vaccine; 2022 Jan; 40(1):162-172. PubMed ID: 34507861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED).
    Lupinacci R; Rupp R; Wittawatmongkol O; Jones J; Quinones J; Ulukol B; Dagan R; Richmond P; Stek JE; Romero L; Koseoglu S; Tamms G; McFetridge R; Li J; Cheon K; Musey L; Banniettis N; Bickham K;
    Vaccine; 2023 Jan; 41(5):1142-1152. PubMed ID: 36621410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.
    Platt HL; Greenberg D; Tapiero B; Clifford RA; Klein NP; Hurley DC; Shekar T; Li J; Hurtado K; Su SC; Nolan KM; Acosta CJ; McFetridge RD; Bickham K; Musey LK;
    Pediatr Infect Dis J; 2020 Aug; 39(8):763-770. PubMed ID: 32639460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).
    Simon JK; Staerke NB; Hemming-Harlo M; Layle S; Dagan R; Shekar T; Pedley A; Jumes P; Tamms G; Sterling T; Musey L; Buchwald UK;
    Vaccine; 2022 Feb; 40(9):1342-1351. PubMed ID: 35039194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3 study of safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine, in children with HIV.
    Wilck M; Barnabas S; Chokephaibulkit K; Violari A; Kosalaraksa P; Yesypenko S; Chukhalova I; Dagan R; Richmond P; Mikviman E; Morgan L; Feemster K; Lupinacci R; Chiarappa J; Madhi SA; Bickham K; Musey L;
    AIDS; 2023 Jul; 37(8):1227-1237. PubMed ID: 36939067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.
    Sobanjo-ter Meulen A; Vesikari T; Malacaman EA; Shapiro SA; Dallas MJ; Hoover PA; McFetridge R; Stek JE; Marchese RD; Hartzel J; Watson WJ; Musey LK
    Pediatr Infect Dis J; 2015 Feb; 34(2):186-94. PubMed ID: 25741971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
    Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
    Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM).
    Wilck M; Cornely OA; Cordonnier C; Velez JD; Ljungman P; Maertens J; Selleslag D; Mullane KM; Nabhan S; Chen Q; Dagan R; Richmond P; Daus C; Geddie K; Tamms G; Sterling T; Patel SM; Shekar T; Musey L; Buchwald UK;
    Clin Infect Dis; 2023 Oct; 77(8):1102-1110. PubMed ID: 37338158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.
    Mohapi L; Pinedo Y; Osiyemi O; Supparatpinyo K; Ratanasuwan W; Molina JM; Dagan R; Tamms G; Sterling T; Zhang Y; Pedley A; Hartzel J; Kan Y; Hurtado K; Musey L; Simon JK; Buchwald UK;
    AIDS; 2022 Mar; 36(3):373-382. PubMed ID: 34750291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study.
    Quinn CT; Wiedmann RT; Jarovsky D; Lopez-Medina E; Rodriguez HM; Papa M; Boggio G; Shou Q; Dagan R; Richmond P; Feemster K; McFetridge R; Tamms G; Lupinacci R; Musey L; Bickham K
    Blood Adv; 2023 Feb; 7(3):414-421. PubMed ID: 36383730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pneumococcal immunogenicity elicited by the PCV13 and PCV15 vaccines in adults 18 through 49 years of age.
    Kanevsky I; Surendran N; McElwee K; Lei L; Watson W; Pride M; Scully I; Karauzum H; Anderson A; Young M
    Vaccine; 2023 Oct; 41(45):6625-6629. PubMed ID: 37793976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis.
    Vadlamudi NK; Parhar K; Altre Malana KL; Kang A; Marra F
    Vaccine; 2019 Feb; 37(8):1021-1029. PubMed ID: 30685252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).
    Bili A; Dobson S; Quinones J; Phongsamart W; Oberdorfer P; Kosalaraksa P; Dagan R; Richmond P; Wilck M; Vallejos W; Nunn C; McFetridge R; Tamms G; Fu R; Lupinacci R; Musey L; Banniettis N; Bickham K;
    Vaccine; 2023 Jan; 41(3):657-665. PubMed ID: 36522265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.